Skip to Main Content

Does the Alzheimer’s drug aducanumab work?

That was the central issue during an interview of Biogen’s head of research and development and chief medical officer, Dr. Al Sandrock, at the STAT Summit in Cambridge, Mass., late last month. Sandrock’s answer, in short, was undoubtedly yes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED